Sanofi
Sarclisa
multiple myeloma
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews Sarclisa for multiple myeloma around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 11h ago
“On March 26, 2026, the European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Sarclisa SC administered via both an OBI and manual injection for the treatment of”